JNJ COVID-19 vaccine is less effective than expected

By: Miguel A. Rodriguez

09:45, 31 January 2021

Novavax stock surge after its potential vaccine proved to be more than 89% effective against COVID-19

USA30 and USA500 extended some losses in early trading today, each of them slipping 1%.

The drop was mostly caused by the new data released by Johnson & Johnson regarding the effectiveness of its COVID-19 vaccine. The Phase III trials showed that the vaccine was 72% effective in the US, 66% in Latin America, and 57% in South Africa, after weeks of late-stage trials. According to #JNJ, the vaccine’s overall effectiveness is 66%.

Following the news, JNJ stock price slipped more than 4%.

On the other hand, Novavax – another biotech company working on a COVID-19 vaccine revealed that its candidate was more than 89% effective. The information is based on the Phase III clinical trial conducted in the UK on 15,000 participants.

According to Novavax CEO, Stanley Erck, the company “has the potential to play an important role in solving this global public health crisis.” 

After the news about Novavax hit the wires, its stock price gained roughly 23%.

Read here about how JNJ has performed in Q4 2020!


Share this article

The information presented herein is prepared by and does not intend to constitute Investment Advice. The information herein is provided as a general marketing communication for information purposes only.Users/readers should not rely solely on the information presented herewith and should do their own research/analysis by also reading the actual underlying research. The content herewith is generic and does not take into consideration individual personal circumstances, investment experience, or current financial situation. 

Key Way Markets Ltd shall not accept any responsibility for any losses of traders due to the use and the content of the information presented herein. Past performance and forecasts are not reliable indicators of future results.